Sign in
Taking peoplePhase 3

Amoxicillin alone versus amoxicillin/clavulanate for community-acquired pneumonia in patients aged 65 years or older, and hospitalized in a non-intensive care unit ward: a non-inferiority randomized controlled trial _ CAPTAIN

Key facts

Who runs it
Centre Hospitalier Universitaire De Nantes
Where
France12 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
326 people, planned
Started
25 Apr 2024
Expected to end
1 Mar 2027
Type of study
Interventional
Record updated
28 January 2026

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Patient aged 65 years or older with or without comorbidities defined by chronic diseases in immunocompetent patients
  • Patient admitted to the hospital for a CAP defined by at least two clinical signs of pneumonia (cough, sputum production, dyspnea, tachypnea, or pleuritic pain, abnormal lung auscultatory sounds, fever (temperature > 38°C) or hypothermia (< 36°C)) and radiological evidence of a new infiltrate confirming pneumonia
  • Written informed consent obtained from patient prior to participation in the study (if the patient is unable to express in writing: consent by a trusted person)
  • Patient understanding oral and written French
  • Patients should be able to call and to answer to a phone call or to be with a relative who can help him to call or to answer questions notably raised by a medical staff belonging to the investigational site

Who cannot take part

  • History of bacterial pneumonia less than 1 month prior to study inclusion
  • Suspected atypical bacteria requiring combined antibiotics therapy
  • Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency, ICU admission)
  • History of jaundice/hepatic impairment associated with amoxicillin/clavulanate acid
  • History of hypersensitivity or allergy to beta-lactam or to any excipients included in study antibiotics
  • Diagnosis confirmed of SAR-Cov2 infection (PCR Test, covid antigen rapid test, or chest computed tomography (CT) scan)
  • Known immunosuppression (asplenia, neutropenia, agammaglobulinemia, transplant, myeloma, lymphoma, known HIV and CD4<200/mm3)
  • Exacerbation of chronic obstructive pulmonary disease
  • Patient requiring ICU admission
  • Subjects with clinical or epidemiological environment leading to suspect a healthcare associated pneumonia with antibiotic resistant pathogen (including long-term care facility)
  • Patient known to be colonized with Pseudomonas aeruginosa or Enterobacteriaceae in the respiratory tract
  • Suspicion of aspiration pneumonia
  • Subject without health insurance
  • Subject without home address or difficulty in terms of follow-up (vacation, job transfer, geographical distance, lack of motivation)
  • Patient under judicial protection
  • Administration of any antibiotic treatment for more than 24 hours before inclusion
  • Participation to another interventional study and having an exclusion period that is still in force during the screening phase or expected participation to another interventional study during participation to the CAPTAIN study
  • Estimated Glomerular Filtration Rate < 30 ml/min
  • Life-threatening presentation expected to lead to possible imminent death
  • Legionella suspected

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

to investigate non-inferiority in terms of clinical efficacy among patients aged 65 years or older, hospitalized in a non-ICU ward for a CAP, and treated with narrow-spectrum (amoxicillin) versus broad-spectrum (amoxicillin/clavulanate) antimicrobial therapy, at Day 30 since hospital admission

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
28 January 2026